We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PTKFY market cap is 3.94B. The company's latest EPS is IDR 11962.8567 and P/E is 0.00.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | |
| Total Revenue | 22.63T | 23.11T | 26.26T | 28.93T | 30.45T |
| Operating Income | 3.54T | 3.5T | 4.49T | 4.49T | 3.9T |
| Net Income | 2.51T | 2.73T | 3.18T | 3.38T | 2.77T |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | |
| Total Assets | 20.26T | 22.56T | 25.67T | 27.24T | 27.06T |
| Total Liabilities | 3.56T | 4.29T | 4.4T | 5.14T | 3.94T |
| Total Equity | 16.71T | 18.28T | 21.27T | 22.1T | 23.12T |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | IDR (IDR) | |
| Operating | 2.5T | 4.22T | 2.83T | 1.27T | 2.91T |
| Investing | -1.9T | -951.22B | -1.06T | -1.37T | -1.14T |
| Financing | -706.92B | -1.1T | -745.18B | -2.41T | -2.44T |
| Market Cap | 3.94B |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 231.28M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 2 (9.72%) |
| Company Name | PT Kalbe Farma (PK) |
| Address |
kalbe building jakarta, java 10510 |
| Website | https://www.kalbe.co.id |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
